Menu
Search
|

Menu

Close
X

Bellicum Pharmaceuticals Inc BLCM.OQ (NASDAQ Stock Exchange Global Market)

7.23 USD
+0.63 (+9.55%)
As of 1:20 AM IST
chart
Previous Close 6.60
Open 6.56
Volume 406,162
3m Avg Volume 160,806
Today’s High 7.33
Today’s Low 6.56
52 Week High 15.51
52 Week Low 5.02
Shares Outstanding (mil) 33.23
Market Capitalization (mil) 377.79
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-2.251
FY16
-2.569
FY15
-1.841
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
1,169.61
5.77
Price to Book (MRQ)
vs sector
3.08
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
25.02
16.52
LT Debt to Equity (MRQ)
vs sector
22.22
12.22
Return on Investment (TTM)
vs sector
-56.99
14.43
Return on Equity (TTM)
vs sector
-67.22
16.13

EXECUTIVE LEADERSHIP

James Brown
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Richard Fair
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
David Spencer
Founder, Chief Scientific Officer, Since 2011
Salary: --
Bonus: --
Kevin Slawin
Founder, Since 2017
Salary: $259,167.00
Bonus: --
Alan Musso
Chief Financial Officer, Treasurer, Since 2014
Salary: $368,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2130 W Holcombe Blvd Ste 800
HOUSTON   TX   77030-3307

Phone: +1832.3841100

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.

SPONSORED STORIES